$ANIX News

Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Completes Dosing Of Fifth Group In Its Phase 1 Clinical Study Of FSHR-Targeted CAR-T Therapy To Treat Ovarian Cancer

Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine

Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Participant In Its Current Phase 1 Study Of FSHR-Targeted CAR-T Therapy For Recurrant Ovarian Cancer Demonstrates Stable Disease After 90 Days Of Treatment; Patient Was Treated In Fifth Dose Cohort

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Announces Second Patient Has Been Treated In Fifth Cohort Of Its Ongoing Phase 1, Dose-Escalating, Clinical Trial Evaluating FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer

HC Wainwright & Co. Maintains Buy on Anixa Biosciences, Lowers Price Target to $6

Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040

IP Australia Grants Patent To Anixa Biosciences’ Breast Cancer Vaccine Technology, Exclusively Licensed From Cleveland Clinic

Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board

Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

Anixa Biosciences Q3 EPS $(0.08) Beats $(0.09) Estimate, Sales $0.00, Same YoY

Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV

Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026

Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy

Anixa Biosciences To Present Data On Its Breast Cancer Vaccine At 2026 Cantor Fitzgerald Global Healthcare Conference

Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know